Skip to Main Content

Author Details

Pablo Tamayo
University of California San Diego
1988
128
65
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
34898046Analysis of CDK12 alterations in a pan-cancer database.Cancer Med2022
35393416CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.Nat Commun2022
34898046Analysis of CDK12 alterations in a pan-cancer database.Cancer Med2022
35393416CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.Nat Commun2022
34460131Human induced pluripotent stem cell-derived macrophages ameliorate liver fibrosis.Stem Cells2021
33542242SPT6 promotes epidermal differentiation and blockade of an intestinal-like phenotype through control of transcriptional elongation.Nat Commun2021
33571541TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.Cancer Lett2021
33669187BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma.Cancers (Basel)2021
34460131Human induced pluripotent stem cell-derived macrophages ameliorate liver fibrosis.Stem Cells2021
34376580KIT<sup>low</sup> Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor.Mol Cancer Ther2021
33571541TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.Cancer Lett2021
33542242SPT6 promotes epidermal differentiation and blockade of an intestinal-like phenotype through control of transcriptional elongation.Nat Commun2021
33669187BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma.Cancers (Basel)2021
34376580KIT<sup>low</sup> Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor.Mol Cancer Ther2021
32142794TEAD1 and TEAD3 Play Redundant Roles in the Regulation of Human Epidermal Proliferation.J Invest Dermatol2020
31913126STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells.Elife2020
32142794TEAD1 and TEAD3 Play Redundant Roles in the Regulation of Human Epidermal Proliferation.J Invest Dermatol2020
32276990Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers.Mol Cancer Res2020
31974273Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.Mol Cancer Ther2020
33046443Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.Cancer Res2020
32530570Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy.Mol Oncol2020
32525984Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples.Nucleic Acids Res2020
32848210HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers.Oncogene2020
33109540WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.Anticancer Res2020
31974273Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.Mol Cancer Ther2020
31913126STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells.Elife2020
33109540WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.Anticancer Res2020
33046443Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.Cancer Res2020
32848210HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers.Oncogene2020
32530570Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy.Mol Oncol2020
32525984Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples.Nucleic Acids Res2020
32276990Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers.Mol Cancer Res2020
31077681Modelling bistable tumour population dynamics to design effective treatment strategies.J Theor Biol2019
31695841The multikinase inhibitor RXDX-105 is effective against neuroblastoma <i>in vitro</i> and <i>in vivo</i>.Oncotarget2019
31582393DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes.Blood Adv2019
31292160Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells.Cancer Res2019
31142745Publisher Correction: Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers.Nat Commun2019
31171722Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.J Biol Chem2019
31077681Modelling bistable tumour population dynamics to design effective treatment strategies.J Theor Biol2019
31513970Cyclin E Overexpression in Human Mammary Epithelial Cells Promotes Epithelial Cancer-Specific Copy Number Alterations.iScience2019
31097695Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers.Nat Commun2019
31695841The multikinase inhibitor RXDX-105 is effective against neuroblastoma <i>in vitro</i> and <i>in vivo</i>.Oncotarget2019
31582393DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes.Blood Adv2019
31292160Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells.Cancer Res2019
31513970Cyclin E Overexpression in Human Mammary Epithelial Cells Promotes Epithelial Cancer-Specific Copy Number Alterations.iScience2019
31097695Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers.Nat Commun2019
31142745Publisher Correction: Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers.Nat Commun2019
31171722Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.J Biol Chem2019
29605183Systematic Evaluation of Molecular Networks for Discovery of Disease Genes.Cell Syst2018
32913982Genomic and Proteomic Alterations in Desmoplastic Small Round Blue-Cell Tumors.JCO Precis Oncol2018
  • 1 - 50 of 256

Recommended Authors

Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 42
Xiaotu Ma
St. Jude Children's Research Hospital
Career Start Year 2006
Number of shared co-authors 11
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 3
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 28
Armand Bankhead
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 2005
Number of shared co-authors 0
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 30
Chao Cheng
Baylor College of Medicine
Career Start Year 2005
Number of shared co-authors 3
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 15
Andrew V Kossenkov
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 4
F??tima Al-Shahrour
Spanish National Cancer Research Centre (CNIO)
Career Start Year 2003
Number of shared co-authors 17
Amy G Robertson
Present address: Dxige Research Inc.
Career Start Year 2003
Number of shared co-authors 32
Florian Markowetz
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2003
Number of shared co-authors 0
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 37
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 40
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 7
Yidong Chen
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 6
Ludmila Danilova
Bloomberg-Kimmel Immunotherapy Institute, Johns Hopkins University School of Medicine
Career Start Year 2001
Number of shared co-authors 40
Joshua M Stuart
University of California at Santa Cruz
Career Start Year 2000
Number of shared co-authors 47
Mariano J Alvarez
Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center
Career Start Year 2000
Number of shared co-authors 15
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 11
Dana Pe'er
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Career Start Year 2000
Number of shared co-authors 13
Andrew J Gentles
Stanford Center for Biomedical Informatics Research, Stanford University
Career Start Year 1999
Number of shared co-authors 12
Celine Lefebvre
The Scripps Research Institute
Career Start Year 1999
Number of shared co-authors 4
Andrey Loboda
Merck & Co., Inc.
Career Start Year 1998
Number of shared co-authors 3
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 30
Aedin C Culhane
Dana-Farber Cancer Institute & Harvard School of Public Health
Career Start Year 1996
Number of shared co-authors 18
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 8
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 19
Yuval Kluger
Yale University School of Medicine
Career Start Year 1984
Number of shared co-authors 2
Rainer Spang
University of Regensburg
Career Start Year 1969
Number of shared co-authors 2

Collaborators

Jill P Mesirov
University of California San Diego
Co-authored papers 66
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 24
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 21
Matthew Meyerson
Broad Institute
Co-authored papers 14
David E Root
Broad Institute of Harvard and MIT
Co-authored papers 14
Scott L Pomeroy
Harvard Medical School
Co-authored papers 14
Eric S Lander
Vanderbilt-Ingram Cancer Center, Vanderbilt University
Co-authored papers 14
Jesse S Boehm
Broad Institute of Harvard and MIT
Co-authored papers 13
Huwate Yeerna
Moores Cancer Center, University of California
Co-authored papers 11
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 10
Aviad Tsherniak
Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard
Co-authored papers 10
Barbara A Weir
Janssen Research and Development LLC
Co-authored papers 10
Aravind Subramanian
Co-authored papers 9
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 9
Michael Reich
university of california san diego
Co-authored papers 7
Gabriela Alexe
Dana-Farber Cancer Institute
Co-authored papers 7
Stuart L Schreiber
Broad Institute
Co-authored papers 6
Rameen Beroukhim
Co-authored papers 6
John G Doench
Co-authored papers 6
Arthur Liberzon
Broad Institute of MIT and Harvard
Co-authored papers 6
Craig H Mermel
Co-authored papers 6
Joshua Gould
Co-authored papers 5
Federica Piccioni
Co-authored papers 5
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 5
Stacey Gabriel
Broad Institute of MIT and Harvard
Co-authored papers 5
Alykhan F Shamji
Center for the Science of Therapeutics, Broad Institute
Co-authored papers 5
Charles W M Roberts
Co-authored papers 4
Chen-Hsiang Yeang
Institute of Statistical Science
Co-authored papers 4
Marcel Kool
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 4
Paul A Clemons
Broad Institute
Co-authored papers 4
Release 1.2